Skip to content

Monthly Archives: August 2013

The Antifungal Therapy in Cancer Patients with Neutropenia Fever

22-Aug-13

Generally, IDSA guideline divided antifungal therapy in cancer patients with FN into two stragetries: empirical antifungal therapy and preemptive antifungal therapy. The former refers to initiation of an antifungal agent at the first possible clinical evidence of fungal infection, which is usually persistent or recrudescent fever or after day 4 of empirical antibiotic therapy. While […]

The Mangement of Relapsed AML

12-Aug-13

The only cure of an adult with relapsed AML is a transplantation. However, three important questions shoul be solved when managing relapsed AML. Whether the patients with relapsed AML should receive a transplantation in untreated relapse rather than undergo reinduction therapy. Which regimen should be offered to patients with relapsed AML for the purpose of […]

Antimicrobial Therapy in Neutropenic and Fever Patients with Cancer (Modification and Duration of Antibiotic Therapy)

10-Aug-13

Once we have initiated empirical antibiotics for fever, all neutropenic patients must be monitored closely for response, adverse effects, emergence of secondary infections, and the development of drug-resistant organisms. With empirical antibiotics, the median time to defervescence in patients with hematologic malignancies, including HSCT, is ~ 5 days, whereas for patients at lower risk with […]